Resverlogix Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVX.TO research report →
Companywww.resverlogix.com
Resverlogix Corp. , a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
- CEO
- Donald J. McCaffrey
- IPO
- 2004
- Employees
- 19
- HQ
- Calgary, AB, CA
Price Chart
Valuation
- Market Cap
- $30.04M
- P/E
- -3.18
- P/S
- 0.00
- P/B
- -0.23
- EV/EBITDA
- -28.44
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 6.67%
- ROIC
- 35.53%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-7,902,965 · -3.51%
- EPS
- $-0.03 · -0.36%
- Op Income
- $-5,203,522
- FCF YoY
- 14.31%
Performance & Tape
- 52W High
- $0.30
- 52W Low
- $0.04
- 50D MA
- $0.11
- 200D MA
- $0.11
- Beta
- 1.04
- Avg Volume
- 31.55K
Get TickerSpark's AI analysis on RVX.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RVX.TO Coverage
We haven't published any research on RVX.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RVX.TO Report →